Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

@article{Addeo2010RandomizedPI,
  title={Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.},
  author={Raffaele Addeo and Michele Caraglia and Sergio Adamo Bellini and Alberto Abbruzzese and L D'Onofrio and Liliana Montella and Antonio Miragliuolo and Rosario Guarrasi and Michele Lanna and Gregorio Cennamo and Vincenzo Faiola and Salvatore A Del Prete},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 4},
  pages={543-8}
}
PURPOSE Approximately 30% to 40% patients with a superficial bladder cancer treated with Bacille Calmette-Guerin (BCG) or epirubicin do not respond; of the initial responders, 35% have a relapse within 5 years. We compare the therapeutic efficacy and toxicity of intravescical infusions of gemcitabine (GEM) with mitomycin (MMC) in patients with a recurrent superficial bladder cancer. PATIENTS AND METHODS Patients with a history of a previously treated, recurrent Ta-T1, G1-G3 bladder… CONTINUE READING
36 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…